GlassScriptPhysician profile
Debbie A Burkhardt
NPI 1154567105
$12,410.08
in general payments reported to CMS, 2019-2025
47 companies · $1,885 in 2025
The $1,885 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,883 · 2022: $2,963 · 2023: $2,411 · 2024: $2,267 · 2025: $1,885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,556 · Education: $7.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,556.40 |
| Education | $7.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,805.93 | 2021-2025 | |
| Novo Nordisk INC | $1,499.89 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $965.43 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $903.82 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $866.86 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $818.08 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Mylan Specialty L.P. | $803.56 | 2021-2024 | Yupelri |
| Lilly USA, LLC | $747.93 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $517.67 | 2021-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $337.29 | 2021-2025 | Veozah, Myrbetriq |
| Corcept Therapeutics | $306.50 | 2024-2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $295.36 | 2021-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $241.61 | 2021-2023 | |
| Abbott Laboratories | $220.47 | 2022-2025 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $219.95 | 2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debbie Burkhardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.